Mean 25-hydroxyvitamin D [25(OH) vitamin D 3 ] levels among groups were between 49 and 65 nmol/L at baseline, and over the 12 weeks of supplementation, the fortified milk improved vitamin D status in both Int groups. CTx-1 and PINP reduced significantly in both Pre-M and PM groups over the 12 weeks, with the changes in CTx-1 being significantly different (P < 0.035) between PM control and PM Int groups at week 12. Parathyroid hormone levels were significantly reduced in all groups over time, except for control PM group where levels increased at 12 weeks. Conclusion The overall pattern of responses indicates that while both regular milk and fortified milk reduce bone resorption in young and older women, fortified milk is measurably more effective. 
Dairy consumption in Chinese populations is low, but milk is potentially of benefit for bone health [7] . Heaney [8] recommended a minimum daily calcium requirement for Chinese women of 1000 mg/day, which is higher than the current recommended intake for China (800 mg/day), but several studies report intakes as low as 230 mg up to 724 mg/day [2, 9] . Higher dietary calcium intake was associated with higher bone mass [2] , and milk supplementation was also of benefit in young Chinese women, increasing bone mass over 6 months, with some effect on markers of bone resorption and an improvement in vitamin D status [7] . A study in postmenopausal Chinese women living in Hong Kong showed that bone loss can be slowed by supplementing with 800 mg calcium per day using fortified milk [10] , and in a study of Chinese women in Malaysia, supplemented with 1200 mg calcium per day from fortified milk, the percentage total body bone loss was significantly reduced compared to the control group [9] . These fortified milks also contained vitamin D ranging between 5 and 10 µg/day, which resulted in improved vitamin D status in both studies. A more recent study in postmenopausal women living in Beijing, China, reported general vitamin D insufficiency and high levels of bone resorption in these women. A 3-month intervention with a high-calcium vitamin D-fortified milk significantly reduced bone resorption and significantly improved vitamin D status [11] [12] [13] .
In short-term studies, the measurement of biochemical markers to assess bone turnover offers an accepted means of determining the effect of a drug treatment or dietary supplement on bone metabolism prior to any significant change in actual bone density [14] . Over the past 20 years, several markers for bone resorption as well as formation have been validated and used in nutritional intervention trials. The choice of the correct and relevant markers is challenging, and the use of various markers in clinical trials has made comparison of different trial outcomes difficult. A recent position paper by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommended two specific markers for use as reference analytes in clinical studies. These are serum C-terminal telopeptide of type I collagen (CTx) as a marker for bone resorption and serum procollagen type I N propeptide (PINP) as a marker for bone turnover [15] . These have been shown to provide information about the response to osteoporosis treatment and their measurement has been standardised. CTx most sensitively reflects the change in bone resorption after Ca supplementation [16] , can predict the rate of bone loss and fracture risk in postmenopausal women [17] [18] [19] and was correlated with 3-year bone mass changes [19] . PINP is not as well characterised but does provide information on bone formation/ turnover and has been evaluated for fracture prediction and for monitoring osteoporosis therapies [18, 20] . It has been shown to respond to milk supplementation over 8-12 weeks [11] [12] [13] .
The purpose of the present study was to evaluate the impact of a high-calcium vitamin D-and FOS-inulin-fortified milk intervention in comparison with regular milk in pre-as well as postmenopausal Chinese women in Malaysia. We hypothesised that the two cohorts of women will respond differently and that the high-calcium milk will impact significantly more than regular milk on biochemical markers of bone resorption and turnover.
Methods
The study was approved by the Ethics Committee For Research Involving Human Subjects, Universiti Putra Malaysia.
Study population, inclusion and exclusion criteria
Women were recruited aged between 30 and 45 years (the premenopausal cohort) or over 55 years of age at least 5 years postmenopause (the postmenopausal cohort) and with a body mass index (BMI) between 17 and 32 kg/m 2 . Exclusion criteria included a history of metabolic bone disease; liver/kidney function tests outside the normal range; diagnosed diabetes mellitus or insulin resistance; lactose intolerance/milk allergy; regular use of calcium and/or vitamin D supplements; regular use of anti-acids containing calcium; more than two units of alcohol per day; smoking; regular use of medication that may influence bone mass; and rheumatoid arthritis/autoimmune disease and fractures in the last 6 months.
Randomisation criteria, procedures and intervention

Recruitment
A total of 975 postmenopausal women and 802 premenopausal community-based women were initially screened for eligibility using a structured questionnaire, and fingerprick cholesterol and glucose tests. From these, 650 women passed the initial screening exercise and agreed to a second-stage screening.
Screening visit
A screening questionnaire on general health was administered at an initial visit. A blood sample was taken between 8 and 10 a.m., after an overnight fast, and haematology, blood minerals and metabolic markers were assessed. If the blood test results were normal, study subjects were asked to have a bone mineral density (BMD) measurement of femoral neck and spine (L1-L4) (using a GE Lunar iDEXA, GE Healthcare, Madison, WI, USA). Body weight was measured to the nearest 0.1 kg using SECA scales, and standing height was measured to the nearest 0.1 cm using a stadiometer. Waist and hip circumference were measured to the nearest 0.1 cm using a nonstretchable measuring tape. The medical history of each subject was recorded at this visit.
Intervention
One hundred and thirty-six premenopausal and 121 postmenopausal Malaysian Chinese women were recruited with written informed consent for the trial. The premenopausal women were randomised into two groups with 69 assigned to the control group and 67 assigned to the intervention (Int) group. The postmenopausal women were randomised into two groups as well with 60 in the control group and 61 in the Int group. The control groups were assigned to receive two servings per day of regular milk (500 mg calcium), and the Int groups were assigned to receive two servings per day of fortified milk (1000 mg calcium for pre-M women and 1200 mg calcium for PM women, plus 96 mg magnesium, 2.4 mg zinc, 15 µg vitamin D and 4 g FOS-inulin) (Anlene™, Fonterra Brands Singapore Pte Ltd) for 12 weeks (Table 1) .
Baseline
Blood sampling
Blood samples were taken between 8 and 10 a.m. (after an overnight fast) for the baseline measurements. Samples were taken to measure plasma markers of bone metabolism (Ctx and PINP) as well as serum calcium, magnesium, phosphorus, lipid profile, glucose, insulin, parathyroid hormone (PTH) and 25(OH) vitamin D 3 . The samples for measuring minerals and metabolic health were collected, processed and analysed immediately by local diagnostic laboratories. Plasma samples for CTx, PINP, PTH and 25(OH) vitamin D 3 were snap-frozen and stored at −80 °C and analysed by Canterbury Health Laboratories, Christchurch, New Zealand.
Anthropometry
Methodology as per screening visit.
Questionnaires completed at baseline
A 3-day diet record, food frequency questionnaire, demographics and a list of all medication taken in the last 6 months were recorded at baseline. 
Blood and bone marker analyses
PTH, CTx and total PINP were analysed by electrochemiluminescence immunoassay using the Roche COBAS ® e411 system (Roche Diagnostics, Indianapolis, IN, USA). 25(OH) vitamin D 3 was analysed using isotope-dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS-MS) [21] .
Compliance
Milk powder was dispensed to each subject at baseline and on a monthly basis thereafter. In addition, phone calls were made to monitor milk consumption of the subjects. Each subject was provided with a monthly diary and asked to record their milk powder intake each day.
Statistical analyses
Based on published data, the within-subject standard deviation for the primary outcome variable CTx was estimated to be 0.045 ng/mL and a representative mean CTx value was taken to be 0.23 ng/mL. The corresponding standard deviation of the treatment difference was calculated as 0.064 ng/mL.
To detect a difference of 20 % (i.e. 0.046 ng/mL) with a power of 90 % and an alpha of 5 %, we required 42 subjects per group. To allow for dropouts, and/or potentially a lower difference (16.5 %), the number of volunteers required was increased to 60 per group. SAS (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. Mixed-model approach of repeated measures was used, and the reported p values for the effects of treatment group, time, and their interaction were based on a compound symmetry covariance pattern model. Data were analysed as (a) raw data, (b) difference from baseline and (c) percentage change from baseline. For (b) and (c), the baseline results (week 0) were included in the model as a covariate and the repeatedmeasures analysis was based on the results from during the intervention (i.e. weeks 4 and 12). All analyses included variables accounting for seasonal effects and compliance as covariates. ANOVA was followed by post hoc comparisons of treatment means using the TukeyKramer test. Measurements were considered to be significantly different if P < 0.05.
Results
Baseline characteristics
The population characteristics for the premenopausal women are shown in Table 2 . The mean ages for these groups were 41 and 42 years with a mean BMI of 22-23 for the control and Int groups, respectively. The mean lumbar spine BMD was normal for both the control (T score = 0.80) and Int (T scores = 0.83) groups. Femoral neck BMD was 0.87 g/cm 2 for both groups with T scores of −0.35 and −0.34 for the control and Int groups. Mean dietary calcium intakes were 319 and 308 mg for the control and Int groups, respectively. The mean 25(OH) vitamin D 3 levels were 48.6 and 53.2 nmol/L for the control versus Int groups. There were no significant differences between the groups at baseline. Table 3 summarises the characteristics of the postmenopausal women. The mean ages for the control and the Int group were 59 and 60 years, respectively, and the mean BMI for the control group was 24.4 versus 23.4 for the Int group (P = 0.05). Lumbar spine BMDs were slightly lower in the Int group (P = 0.02) with T scores of −0.32 for the control and −0.77 for the Int groups. For the femoral neck, BMDs were normal with the T scores at −0.76 for the control and −0.94 for the Int group. Mean calcium intake from the food frequency questionnaire for these groups was 340 (control) and 366 mg/day (Int). Baseline 25(OH) vitamin D 3 was 64.7 nmol/L for the control group versus 62.5 nmol/L for the Int group. No significant differences in age, femoral neck BMD, calcium intake or 25(OH) vitamin D 3 levels were detected.
Impact of intervention
General health and blood minerals
For all women, both pre-and postmenopausal, general measures of health including fasting blood glucose and fasting lipid profiles were within normal ranges at weeks 0 and 12 (Table 4 ). Blood minerals including calcium, magnesium and phosphorus were within normal ranges for both cohorts. While there were few significant differences between the Int and the control groups (across weeks), there were some significant changes between week 0 and week 12 (across groups). In Pre-M, calcium was significantly higher in the Int group than in the control group throughout the trial (P = 0.014), and in PM, total cholesterol tended to be higher in the control group than in the Int group throughout the trial (P = 0.075). Calcium increased significantly between week 0 and week 12 in both Int and control groups in the Pre-M (P < 0.001) and to a lesser extent in the PM (P = 0.096). Total cholesterol, on the other hand, decreased significantly between week 0 and week 12 in both Int and control groups in the PM (P < 0.01) and to a lesser extent in the Pre-M (P = 0.086). Furthermore, in Pre-M, magnesium decreased significantly in both groups (P = 0.029), and in PM, glucose increased significantly in both groups (P = 0.009).
Vitamin D status
For assessment of the vitamin D status of the women, the Institute of Medicine Guidelines (IOM) were used where a level of >50 nmol/L is adequate, and < 50 nmol/L is insufficient [22] . In the premenopausal women, 58 % of the control group had 25(OH) vitamin D 3 levels that were insufficient at baseline using a cut-off of 50 nmol/L (data not shown), with 45 % insufficient at baseline in the Int group. These levels changed to 22 % insufficient in the control group and 15 % insufficient in the Int group at week 12.
For the postmenopausal women control group, 28 % were insufficient at baseline. Over the 12 weeks of supplementation, the percentage with insufficiency increased to 52 %. In the Int group, 33 % were insufficient at baseline and their status remained unchanged over the 12 weeks of supplementation. Mean serum 25(OH) vitamin D 3 levels at baseline were sufficient (equal to or >50 nmol/L) [22] for both the preand postmenopausal women in the control as well as the Int groups (Tables 2, 3 ). Table 5 in the Int group (57.3-71.5 nmol/L, P = 0.024). Figure 1a , b shows the change from baseline for both pre-and postmenopausal women.
Change in PTH Figure 2a shows the change from baseline in PTH levels in the groups of pre-and postmenopausal women over time, while Table 5 shows the PTH levels for the different time points. In the premenopausal women, PTH reduced significantly from baseline to weeks 4 and 12 in both the control and the Int groups (P < 0.001 for the effect of week) ( Table 5 ). PTH levels in the postmenopausal control group tended to increase from 3.62 to 3.86 pmol/L over the 12 weeks (P > 0.05). In the Int group, however, PTH tended to decrease from 3.72 to 3.55 pmol/L (P > 0.05). At week 12, the change from baseline in PTH in the Int group was significantly different from the change from baseline in the control group (P < 0.01 between groups, Fig. 2b ). Figure 3a shows the changes from baseline in CTx over the 12 weeks in the premenopausal women, and Table 5 shows CTx levels for the different time points. The women responded with a significant decrease in CTx for both the control and Int groups (P = 0.016, data not shown). In the control group, CTx reduced from 0.26 to 0.21 and then 0.23 µg/L over the 12 weeks (P = 0.058). In the Int group, CTx reduced from 0.25 to 0.22 µg/L (P = 0.024) over the 12 weeks. There were no significant differences between the groups at any time point. Figure 3b shows the changes from baseline in CTx for the postmenopausal women, over the 12 weeks of supplementation, and Table 5 shows CTx levels for the different time points. Both the control and the Int groups of women exhibited bone turnover within the typical range for postmenopausal women. Mean plasma CTx values were approximately 0.4 μg/L at baseline. In the control group, plasma CTx remained relatively stable between baseline and week 12 (0.44 to 0.40 µg/L, P > 0.05). In the Int group, CTx reduced from 0.46 to 0.36 µg/L (P < 0.001) over the first 4 weeks and remained at this level till week 12. The change from baseline in CTx for the Int groups was significantly different from the control group at week 12 (P = 0.035). Figure 4a , b depict the changes from baseline in PINP in both the pre-and the postmenopausal women, and Table 5 shows PINP levels for the different time points.
Change in CTx
Change in PINP
For the premenopausal women, PINP significantly decreased over the 12-week intervention period (P < 0.001) with the difference between weeks 4 and 12 being significant (P < 0.001), but there was no difference in the pattern of reduction between the control and Int groups (P = 0.114 for the interaction). In the control group, PINP remained stable between weeks 0 and 4 (33.3-32.7 µg/L) and then reduced to 30.40 µg/L at week 12. In the Int group, PINP remained constant between weeks 0 and 4 (35.7-34.0 µg/L) and then reduced to 30.1 µg/L at week 12.
As for the premenopausal women, PINP significantly decreased over the 12-week intervention period (P < 0.001) in the postmenopausal women with the difference between weeks 4 and 12 being significant (P < 0.001), but there was no difference in the pattern of reduction between the control and Int groups (P = 0.197 for the interaction). In the control group, PINP remained stable between weeks 0 and 4 (48.9 and 48.8 µg/L) and then reduced to 44.0 µg/L at week 12.
In the Int group, PINP remained constant between weeks 0 and 4 (47.9-45.7 µg/L) and then reduced to 40.4 µg/L at week 12. There were no significant differences between the groups of post-as well as premenopausal women.
Discussion
Supplementation of healthy postmenopausal Chinese women with calcium-, vitamin D-and FOS-inulin-fortified milk for 12 weeks significantly reduced bone resorption and improved vitamin D status. In premenopausal women, vitamin D status improved over the 12 weeks, but the responses of PTH, CTx and PINP were less pronounced. In postmenopausal women, the fortified milk did impact on bone metabolism significantly more than regular milk.
Habitual mean calcium intake for both the postmenopausal and premenopausal cohorts of women was less than 400 mg/day in the present study which is well below the recommended intake of 900 mg for Chinese women in Hong Kong [7] and 1000 mg for Asian women in general [8] . Bacon et al. [23] and Woo et al. [7] reported calcium intakes of between 300 and 500 mg/day for premenopausal Chinese women living in Hong Kong. Haines et al. [24] reported an intake of less than 400 mg in a population of Chinese postmenopausal women in Hong Kong and Kruger et al. [12, 13] reported that postmenopausal women living in Beijing had a calcium intake of less than 500 mg/day. Low calcium intake and insufficient vitamin D status have been reported as risk factors for osteoporosis in Asian women [3] , which may indicate that the two populations described in this intervention study are at risk for low bone mass and increased risk of fractures. However, our data do indicate that the postmenopausal women who participated in the study were vitamin D sufficient, while the premenopausal women were more likely to be insufficient The minimum level of serum 25(OH) vitamin D 3 estimated to be optimal for fracture prevention varies between 50 and 80 nmol/L [23, 25] . The vitamin D status for the premenopausal women was lower in comparison with the postmenopausal women with 58 % of control and 45 % of Int group being insufficient at baseline (based on sufficiency = 50 nmol/L [22] ) compared to 28 and 33 % in PM. Among the postmenopausal women who participated in our trial, insufficiency increased to 52 % in the control group, but remained constant at 33 % in the Int group, indicating that vitamin D status declined over the 12 weeks in the control while remaining stable in the Int group. If these levels are considered in the light of the guidelines provided by the Endocrine Society [26] , where sufficient levels of 25(OH) D 3 are considered to be >72.5 nmol/L, most women would be classified as being deficient with 58 and 45 % of the control and Int groups of the premenopausal women and 28 and 33 % of the PM women being deficient at the start of the trial.
In the premenopausal cohorts, the 25(OH) vitamin D 3 levels in the control group remained similar over the 12 weeks of supplementation (52.0 vs. 52.5 nmol/L), whereas the Int group's levels increased significantly from 54.6 to 63.1 nmol/L (P < 0.031) and were significantly higher than the control group at week 12 (P < 0.001).
In the postmenopausal women, serum 25(OH) vitamin D 3 levels increased significantly over the 12 weeks of supplementation with the fortified milk (57.3-71.5 nmol/L, P = 0.024), while status remained similar over the 12 weeks in the control group (59.3 vs. 63.5 nmol/L). A previous study in Indonesian women showed that increasing daily vitamin D intake by 10 µg per day resulted in a significant enhancement of vitamin D status over 16 weeks from a mean serum value of 44 nmol/L to a mean of 58 nmol/L [11] . The optimal vitamin D status to support the skeleton was suggested to be between 50 and 80 nmol/L, but further estimations now indicate that a minimum desirable level could be 70-80 nmol/L [25, 26] . It was further suggested that the average older woman will need an intake of at least 20-25 µg per day of vitamin D to reach a serum level of 75 nmol/L. In an earlier review by Vieth [27] , a daily dose of 10 µg per day for 2.5 months was not able to increase measured 25(OH) vitamin D 3 levels above 60 nmol/L from a baseline of 40, and a dose of 25 µg increased levels over 2.5 months from 40 to 60 nmol/L in the respective older populations. In our study, the fortified milk supplied 15 µg/ day which was sufficient to increase vitamin levels of postmenopausal women to 72 nmol/L (almost sufficient as per the Endocrine Society [26] ) from a baseline of 59 nmol/L, and of premenopausal women from 54.3 to 63.12 nmol/L after 12 weeks. Our measured levels in the postmenopausal women compared well with those reported for Chinese women living in Malaysia [28, 29] , which both reported a mean of 68.8 nmol/L and as well as a significant inverse relationship between vitamin D status and PTH levels.
The increase in vitamin D status observed in both the Int groups should improve calcium absorption as Aloia et al. [30] confirmed that calcium absorption will increase with improvement of 25(OH) vitamin D 3 levels between 40 and 130 nmol/L. Increased calcium absorption would support maintenance of bone health in the premenopausal women and help reduce bone loss in the postmenopausal women. Green et al. [31] estimated that for premenopausal women living in Jakarta and Kuala Lumpur, 52 nmol/L was the threshold concentration for plasma 25(OH) vitamin D 3 levels above which no further suppression of PTH would occur. This relationship was not dependent on calcium intakes. In addition, Bacon et al. [23] reported that in Chinese premenopausal women living in Hong Kong, PTH levels did not drop any further after serum 25(OH) vitamin D 3 levels reached 42 nmol/L. However, even though the premenopausal women in our study were already at mean levels of 52-55 nmol/L at baseline, both milks reduced PTH levels at 4 weeks although we did not observe any significant further reduction after week 4. The sudden decrease in the PTH levels of the control pre-MP group was somewhat unexpected and is still to be explained. Several studies in postmenopausal women have reported not only an inverse relationship between 25(OH) vitamin D 3 and PTH, but also with BMD [9, 27, [32] [33] [34] [35] [36] . Chee et al. [9] observed a 50 % rise in the PTH levels of the postmenopausal control group over the 2 years of the milk supplementation trial, while we observed a 6 % rise over 12 weeks in the control PM women and a 3 % decrease in PTH in the women taking the fortified milk. The population described by Chee et al., however, had a very low vitamin D status which together with ageing will affect PTH levels as well as bone resorption. For our study, in the postmenopausal group supplemented with control milk, increased PTH levels indicate that the dose of calcium from the daily milk, as well as the small changes in vitamin D status was not sufficient to suppress the rise in PTH due to ageing, whereas the fortified milk was able to reduce PTH levels over the 12 weeks of intervention.
Very few studies report changes in bone markers due to milk supplementation in pre-and postmenopausal women. Woo et al. [7] supplemented 441 premenopausal Chinese women with fortified milk containing 1000 mg calcium for 2 years and reported no differences over 2 years in bone markers between the milk group and the control group who did not receive any milk. The reduction in the measured bone markers in the control group was deemed to be due to attainment of peak bone mass and reduction in bone turnover. In Caucasian women aged between 20 and 35, milk fortified with 1000 mg calcium caused a significant reduction in plasma CTx and PINP compared to the control group over 16 weeks (CTx > 30 %, PINP > 15 %) [37] .
In the premenopausal women in our study, supplementation with the fortified milk resulted in a drop of 9-12 % CTx levels in the Int group, while dropping by 17 % in the first 4 weeks of supplementation in the control group but then increasing by 9 % over the next 8 weeks. After 12 weeks, the percentage changes in the control group were slightly less than the Int group (7.3 vs. 11.8 %). The average levels for CTx in the premenopausal women at baseline were lower than those reported for premenopausal women living in Italy (0.43 µg/L) [38] , France (0.29 µg/L) and Denmark (0.39 µg/L) [39] but similar to levels reported for women living in the USA (0.28 µg/L) [40] . The levels we measured were not corrected for use of hormonal contraceptives [39, 40] , as only 8 of the women reported use during the 12 weeks.
Regarding postmenopausal women, Huang et al. [41] reported a reduction in PTH levels, bone resorption and bone loss in postmenopausal Chinese women in response to 1000 mg of calcium and 10 µg of vitamin D for 12 months. Fortified milk supplementation (800 mg calcium; 6 µg vitamin D) for 3 years improved vitamin D status and prevented bone loss in postmenopausal Chinese women residing in Hong Kong [7] , and in older women living in Beijing, China, milk fortified with 900 mg calcium and 6.4 μg vitamin D significantly reduced CTx and PTH levels over 12 weeks of supplementation [12, 13] .
In this study, in the postmenopausal Int group, supplementation with the fortified milk resulted in a significant reduction in bone resorption. The mean CTx at baseline was between 0.44 and 0.46 µg/L which is within the range previously reported for postmenopausal women [42, 43] . Supplementation with regular milk decreased the mean CTx levels of the control group by 11 % within 4 weeks of supplementation, and no further reduction was observed. In the Int group, CTx levels fell by 17 % in the first 4 weeks and remained at this level till week 12. These changes were very similar to the response recorded for Chinese postmenopausal women living in Beijing, China [12, 13] .
In terms of bone turnover, in the premenopausal women, PINP decreased by 7 and 13 % in the control and Int groups, respectively, over the 12 weeks, indicating an overall reduction in bone turnover associated with milk supplementation. The fortified milk had a slightly greater effect than the regular milk control. Determinants for bone turnover markers in premenopausal women include use of the contraceptive pill, age, body mass index and vitamin D status [38] .
In the postmenopausal women, the baseline levels of PINP (48-49 µg/L) were higher than those reported by Liu et al. [44] for 244 postmenopausal Chinese women aged between 45 and 65 years. Circulating PINP mainly reflects the synthesis rate of type I collagen, and as bone turnover increases with ageing and menopausal stage, the measured levels in older women will increase. There is, however, an additional impact of lower vitamin D status and low habitual calcium intakes in our postmenopausal women, which could lead to the measured high baseline bone resorption and turnover [45, 46] . In this study, PINP responded to both the control and the fortified milk supplementation, decreasing by 9 and 15 %, respectively, over the 12 weeks. Similarly, milk supplementation in postmenopausal women living in Beijing reduced PINP up to 18 % over 12 weeks [12, 13] .
Both CTx and PINP can be predictive of future bone loss [18, 43, 47] and future risk of fracture [47] . CTx may reflect parameters of bone strength unrelated to BMD, such as micro-architectural deterioration of bone tissue resulting in micro-cracks which increase the risk of fracture [49, 50] , while PINP is significantly associated with risk of all fractures. CTx was shown to be inversely correlated with BMD of the lumbar spine in 665 healthy Chinese women aged between 20 and 80 years [42] . The patterns of change for CTx and PINP observed in the postmenopausal Int group could over time result in lowering of bone loss and possibly maintenance of bone structure. The control milk did have some effects on resorption but not as pronounced as those from the fortified milk. The response by the premenopausal group to the fortified milk was less pronounced and seemed to stabilise after 3 months. These women appeared to respond to both milks. The mean age of the premenopausal group was [41] [42] , an age where bone should be well maintained and not yet impacted on by hormonal changes due to menopause, possibly resulting in an observed lesser response to the milk interventions. The decrease in turnover in the pre-MP women consuming milk, however, if continued over time, could result in significant preservation of bone.
In conclusion, the addition of calcium-, vitamin D-, and FOS-inulin-fortified milk to the diet of premenopausal and postmenopausal Chinese women significantly reduced bone resorption and maintained vitamin D status over 12 weeks in the older women while improving vitamin D status and reducing bone turnover in the younger women. The consumption of regular milk by these Chinese women had some impact on markers of bone metabolism, although fortified milk was measurably more effective especially in postmenopausal women. If sustained long term, these changes could help preserve BMD and reduce future fracture risk of both age groups. Supplementation of traditionally low calcium diets with a fortified milk drink could have significant public health benefits for Asia's large and rapidly ageing population.
